Seagen Future Growth

Future criteria checks 5/6

Seagen is forecast to grow earnings and revenue by 65.7% and 23.1% per annum respectively. EPS is expected to grow by 65.4% per annum. Return on equity is forecast to be 19.2% in 3 years.

Key information

65.7%

Earnings growth rate

65.4%

EPS growth rate

Biotechs earnings growth	0%
Revenue growth rate	23.1%
Future return on equity	19.2%
Analyst coverage	Good
Last updated	07 Jul 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:SGEN * - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	4,094	395	683	635	18
12/31/2024	3,160	-139	74	61	19
12/31/2023	2,313	-565	-407	-361	18
3/31/2023	2,056	-649	-585	-487	N/A
12/31/2022	1,962	-610	-531	-454	N/A
9/30/2022	1,864	-637	-719	-658	N/A
6/30/2022	1,778	-740	-652	-590	N/A
3/31/2022	1,669	-690	-653	-590	N/A
12/31/2021	1,574	-674	-551	-499	N/A
9/30/2021	1,746	-333	-82	-26	N/A
6/30/2021	2,383	597	756	814	N/A
3/31/2021	2,273	661	736	800	N/A
12/31/2020	2,176	614	774	857	N/A
9/30/2020	1,864	472	571	656	N/A
6/30/2020	1,016	-256	-312	-228	N/A
3/31/2020	956	-314	-259	-176	N/A
12/31/2019	917	-159	-234	-164	N/A
9/30/2019	801	-304	-234	-176	N/A
6/30/2019	758	-280	-172	-127	N/A
3/31/2019	709	-124	-143	-114	N/A
12/31/2018	655	-223	-225	-204	N/A
9/30/2018	610	-162	-183	-182	N/A
6/30/2018	576	-45	-179	-179	N/A
3/31/2018	514	-177	-221	-203	N/A
12/31/2017	482	-126	-148	-119	N/A
9/30/2017	458	-121	-183	-132	N/A
6/30/2017	429	-203	-210	-155	N/A
3/31/2017	416	-180	-178	-143	N/A
12/31/2016	418	-140	N/A	-97	N/A
9/30/2016	406	-110	N/A	-101	N/A
6/30/2016	384	-105	N/A	-110	N/A
3/31/2016	366	-119	N/A	-124	N/A
12/31/2015	337	-120	N/A	-133	N/A
9/30/2015	318	-122	N/A	-135	N/A
6/30/2015	309	-111	N/A	-106	N/A
3/31/2015	301	-82	N/A	-64	N/A
12/31/2014	287	-76	N/A	-60	N/A
9/30/2014	280	-65	N/A	-33	N/A
6/30/2014	275	-73	N/A	9	N/A
3/31/2014	280	-63	N/A	6	N/A
12/31/2013	269	-63	N/A	-1	N/A
9/30/2013	266	-57	N/A	43	N/A
6/30/2013	245	-47	N/A	-12	N/A
3/31/2013	220	-58	N/A	9	N/A
12/31/2012	211	-54	N/A	11	N/A
9/30/2012	196	-70	N/A	-76	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGEN * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.6%).

Earnings vs Market: SGEN * is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SGEN * is expected to become profitable in the next 3 years.

Revenue vs Market: SGEN *'s revenue (23.1% per year) is forecast to grow faster than the MX market (6.2% per year).

High Growth Revenue: SGEN *'s revenue (23.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SGEN *'s Return on Equity is forecast to be low in 3 years time (19.2%).

Seagen Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. Revises Earnings Guidance for the Year 2022

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc

Second quarter 2022 earnings released: US$0.73 loss per share (vs US$0.47 loss in 2Q 2021)

Seagen Inc. Revises Earnings Guidance for the Year 2022

Insufficient new directors

Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022

Merck Reportedly in Advanced Talks to Buy Seagen

Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab

Merck Reportedly Pushes Forward with Potential Deal for Seagen

Merck, Other Suitors Reportedly Interested in Acquiring Seagen

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Insufficient new directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies